|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Biomarkers for the early diagnosis of hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC) is the fifth most common cancer and the second leading cause of cancer-related deaths worldwide. Although the prognosis of patients with HCC is generally poor, the5-year survival rate is > 70% if patients are diagnosed at an early stage. However, early diagnosis of HCC is complicated by the coexistence of inflammation and cirrhosis. Thus, novel biomarkers for the early diagnosis of HCC are required. Currently, the diagnosis of HCC without pathological correlation is achieved by analyzing serum α.fetoprotein levels combined with imaging techniques. Advances in genomics and proteomics platforms and biomarker assay techniques over the last decade have resulted in the identification of numerous novel biomarkers and have improved the diagnosis of HCC. The most promising biomarkers,such as glypican-3, osteopontin, Golgi protein-73 and nucleic acids including microRNAs, are most likely to become clinically validated in the near future. These biomarkers are not only useful for early diagnosis of HCC, but also provide insight into the mechanisms driving oncogenesis. In addition, such molecular insight creates the basis for the development of potentially more effective treatment strategies. In this article,we provide an overview of the biomarkers that are currently used for the early diagnosis of HCC. | Nobuhiro Tsuchiya Yu Sawada Itaru Endo Keigo Saito Yasushi Uemura Tetsuya Nakatsura | 2015 | World Journal of Gastroenterology2015，21，37： | 72 |
| 2 | Congenital tracheoesophageal fistula successfully diagnosed by CT esophagography显示文摘Tracheoesophageal 管(TEF ) 或 bronchoesophageal 管可能对损伤先天、煽动性、肿瘤,或第二等。先天的 TEF 或 bronchoesophageal 管通常与食道的闭锁被联系并且乐意地在幼年期被诊断。但是如果它没与食道的闭锁被联系,它可以坚持直到成人生活。一些理论被建议了在诊断解释这延期。我们在场有先天的 TEF 的一个 70 岁的人的一个盒子。TEF 被 multidetector 排 CT esophagography 成功地诊断。 | Koichi Nagata Yoshito Kamio Tamaki Ichikawa Mitsutaka Kadokura Akihiko Kitami Shungo Endo Haruhiro Inoue Shin-Ei Kudo | 2006 | World Journal of Gastroenterology2006，12，9： | 32 |
| 3 | Therapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis显示文摘Ulcerative colitis (UC) is a chronic inflammatory bowel disease that may become intractable when treated with conventional medications such as aminosalicylates, corticosteroids, and azathioprine. The herbal medicine Qing Dai has traditionally been used in Chinese medicine to treat UC patients, but there is a lack of published data on the efficacy of Qing Dai in UC treatment. We report several cases of patients with intractable UC who take Qing Dai in a retrospective observational study. Furthermore, we explore the mechanisms of action of Qing Dai. Nine patients with active UC who received conventional medications but wished to receive Qing Dai as an alternative medication were included in our analysis. The UC severity level was determined based on the clinical activity index (CAI). Additionally, 5 of the 9 patients were endoscopically evaluated according to the Matts grading system. Each patient received 2 g/d of Qing Dai orally and continued taking other medications for UC as prescribed. Electron spin resonance was applied to explore the mechanisms of action of Qing Dai. After 4 mo of treatment with Qing Dai, the CAI score decreased from 8.3 ± 2.4 to 2.4 ± 3.4 (mean ± SD; P < 0.001). Similarly, the endoscopic Matts grade decreased from 3.4 ± 0.5 to 2.2 ± 0.8 (P = 0.02). Six of 7 patients who were on prednisolone upon enrollment in the study were able to discontinue this corticosteroid. Electron spin resonance revealed that Qing Dai possesses strong hydroxyl radical scavenging activity. Qing Dai showed significant clinical and endoscopic efficacy in patients who failed to respond to conventional medications. Scavenging of hydroxyl radicals appears to be a potential mechanism through which Qing Dai acts, but the significance of the scavenging ability of Qing Dai with respect to the anti-inflammatory effect in UC patients warrants further investigation. | Hideo Suzuki Tsuyoshi Kaneko Yuji Mizokami Toshiaki Narasaka Shinji Endo Hirofumi Matsui Akinori Yanaka Aki Hirayama Ichinosuke Hyodo | 2013 | World Journal of Gastroenterology2013，19，17： | 19 |
| 4 | Potentiality of immunotherapy against hepatocellular carcinoma显示文摘Hepatocellular carcinoma(HCC),the predominant form of primary liver cancer,is the fifth most common cancer worldwide and the second leading cause of cancer-related death. Despite the high incidence,treatment options remain limited for advanced HCC,and as a result prognosis continues to be poor. Current therapeutic options,surgery,chemotherapy and radiotherapy,have only modest efficacy. New treatment modalities to prolong survival and to minimize the risk of adverse response are desperately needed for patients with advanced HCC. Tumor immunotherapy is a promising,novel treatment strategy that may lead to improvements in both treatment-associated toxicity and outcome. The strategies have developed in part through genomic studies that have yielded candidate target molecules and in part through basic biology studies that have defined the pathways and cell types regulating immune response. Here,we summarize the various types of HCC immunotherapy and argue that the newfound field of HCC immunotherapy might provide critical advantages in the effort to improve prognosis of patients with advanced HCC. Already several immunotherapies,such as tumor-associated antigen therapy,immune checkpoint inhibitors and cell transfer immunotherapy,have demonstrated safety and feasibility in HCC patients. Unfortunately,immunotherapy currently has low efficacy in advanced stage HCC patients; overcoming this chal lenge will place immunotherapy at the forefront of HCC treatment,possibly in the near future. | Nobuhiro Tsuchiya Yu Sawada Itaru Endo Yasushi Uemura Tetsuya Nakatsura | 2015 | World Journal of Gastroenterology2015，21，36： | 19 |
| 5 | Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude显示文摘AIM:To use leptin-deficient(ob/ob) mice with demonstrated differences in steatosis levels to test a new diagnostic method using the acoustical structure quantification(ASQ) mode and the associated analytical parameter,'focal disturbance ratio'(FD-ratio).METHODS:Nine ob/ob mice,at 5,8,and 12 wk of age(n = 3 in each age group),were used as models for hepatic steatosis.Echo signals obtained from ultrasonography in the mice were analyzed by ASQ,which uses a statistical analysis of echo amplitude to estimate inhomogeneity in the diagnostic region.FD-ratio,as calculated from this analysis,was the focus of the present study.FD-ratio and fat droplet areas and sizes were compared between age groups.RESULTS:No fibrosis or inflammation was observed in any of the groups.The fat droplet area significantly(P < 0.01) increased with age from 1.25% ± 0.28% at 5 wk to 31.07% ± 0.48% at 8 wk to 51.69% ± 3.19% at 12 wk.The median fat droplet size also significantly(P < 0.01) increased with age,from 1.33(0.55-10.52) m at 5 wk,2.82(0.61-44.13) m at 8 wk and 6.34(0.66-81.83) m at 12 wk.The mean FD-ratio was 0.42 ± 0.11 at 5 wk,0.11 ± 0.05 at 8 wk,and 0.03 ± 0.02 at 12 wk.The FD-ratio was significantly lower at 12 wk than at 5 wk and 8 wk(P < 0.01).A significant negative correlation was observed between the FD-ratio and either the fat droplet area(r =-0.7211,P = 0.0017) or fat droplet size(r =-0.9811,P = 0.0052).CONCLUSION:This tool for statistical analysis of signals from ultrasonography using the FD-ratio can be used to accurately quantify fat in vivo in an animal model of hepatic steatosis,and may serve as a quantitative biomarker of hepatic steatosis. | Hidekatsu Kuroda Keisuke Kakisaka Naohisa Kamiyama Takayoshi Oikawa Mio Onodera Kei Sawara Kanta Oikawa Ryujin Endo Yasuhiro Takikawa Kazuyuki Suzuki | 2012 | World Journal of Gastroenterology2012，18，29： | 15 |
| 6 | A candidate targeting molecule of insulin-like growth factor-Ⅰ receptor for gastrointestinal cancers显示文摘Advances in molecular research in cancer have brought new therapeutic strategies into clinical usage.One new group of targets is tyrosine kinase receptors,which can be treated by several strategies,including small molecule tyrosine kinase inhibitors(TKIs) and monoclonal antibodies(mAbs).Aberrant activation of growth factors/receptors and their signal pathways are required for malignant transformation and progression in gastrointestinal(GI) carcinomas.The concept of targeting specif ic carcinogenic receptors has been validated by successful clinical application of many new drugs.Type I insulin-like growth factor(IGF) receptor(IGF-IR) signaling potently stimulates tumor progression and cellular differentiation,and is a promising new molecular target in human malignancies.In this review,we focus on this promising therapeutic target,IGF-IR.The IGF/IGF-IR axis is an important modifier of tumor cell proliferation,survival,growth,and treatment sensitivity in many malignant diseases,including human GI cancers.Preclinical studies demonstrated that downregulation of IGF-IR signals reversed the neoplastic phenotype and sensitized cells to anticancer treatments.These results were mainly obtained through our strategy of adenoviruses expressing dominant negative IGF-IR(IGF-IR/dn) against gastrointestinal cancers,including esophagus,stomach,colon,and pancreas.We also summarize a variety of strategies to interrupt the IGFs/IGF-IR axis and their preclinical experiences.Several mAbs and TKIs targeting IGF-IR have entered clinical trials,and early results have suggested that these agents have generally acceptable safety profiles as single agents.We summarize the advantages and disadvantages of each strategy and discuss the merits/demerits of dual targeting of IGF-IR and other growth factor receptors,including Her2 and the insulin receptor,as well as other alternatives and possible drug combinations.Thus,IGF-IR might be a candidate for a molecular therapeutic target in human GI carcinomas. | Yasushi Adachi Hiroyuki Yamamoto Hirokazu Ohashi Takao Endo David P Carbone Kohzoh Imai Yasuhisa Shinomura | 2010 | World Journal of Gastroenterology2010，16，46： | 14 |
| 7 | 1200a来洪湖演变的环境磁学记录显示文摘对取自洪湖的 140cm沉积物样芯进行了环境磁学测量,分析了所获得的环境磁学参数随深度变化的曲线,结果表明,沉积物磁性特征由稳定单畴(SSD)和细粘滞性 (FV)亚铁磁性矿物所主导,磁性矿物颗粒由下至上粒径逐渐减小。结合AMS测年和地球化学分析,可以推断出洪湖在 1200a来经历了沼泽沉积和湖相沉积。并且磁性特征的变化与气候的变化大致对应:磁性参数较大值对应着冷干的气候条件;水热条件增强时,磁性参数值下降。较好记录了湖泊随气候的扩张和缩小过程,同时也反映了人类活动的影响。 | 陈萍 何报寅 杜耘 Kunihiko Endo 杨汉东 | 2005 | 沉积学报2005，23，1： | 14 |
| 8 | Immunoglobulin G4-related gastrointestinal diseases, are they immunoglobulin G4-related diseases?显示文摘In immunoglobulin G4(IgG4)-related disease(RD),organ enlargement or nodular lesions consisting of abundant infiltration of lymphocytes and IgG4-positive plasma cells and fibrosis are seen in various organs.Although infiltration of many IgG4-positive plasma cells is detected in the gastric and colonic mucosa and major duodenal papilla of patients with autoimmune pancreatitis,it cannot be diagnosed as a gastrointestinal lesion involved in IgG4-RD,because none of the following is observed in these lesions:a mass-like formation;dense fibrosis;or obliterative phlebitis.Based on our review of the literature,there appear to be two types of IgG4-related gastrointestinal disease.One is a gastrointestinal lesion showing marked thickening of the wall of the esophagus and stomach,consisting of dense fibrosis with abundant infiltration of IgG4-positive plasma cells,which usually show submucosal spreading.The other is an IgG4-related pseudotumor occurring in gastrointestinal regions such as the stomach,colon,and major duodenal papilla,showing polypoid or mass-like lesions.Most solitary IgG4-related gastrointestinal lesions that are not associated with other IgG4-RD appear to be difficult to diagnose.It is of utmost importance to rule out malignancy.However,these lesions may respond to steroid therapy.To avoid unnecessary resection,IgG4-related gastrointestinal diseases should be considered in the differential diagnosis. | Satomi Koizumi Terumi Kamisawa Sawako Kuruma Taku Tabata Kazuro Chiba Susumu Iwasaki Yuka Endo Go Kuwata Koichi Koizumi Tooru Shimosegawa Kazuichi Okazaki Tsutomu Chiba | 2013 | World Journal of Gastroenterology2013，19，35： | 12 |
| 9 | Micro RNA-320 family is downregulated in colorectal adenoma and affects tumor proliferation by targeting CDK6显示文摘AIM: To investigate the microR NA(miR NA) expression during histological progression from colorectal normal mucosa through adenoma to carcinoma within a lesion. METHODS: Using microarray, the sequential changes in miR NA expression profiles were compared in colonic lesions from matched samples; histologically, nonneoplastic mucosa, adenoma, and submucosal invasive carcinoma were microdissected from a tissue sample. Cell proliferation assay was performed to observe the effect of miR NA, and its target genes were predicted using bioinformatics approaches and the expression profile of SW480 transfected with the miR NA mimics. mR NA and protein levels of the target gene in colon cancer cell lines with a mimic control or miR NA mimics were measured using qR TPCR and Western blotting. The expression levels of miR NA and target gene in colorectal tissue samples were also measured.RESULTS: Microarray analysis identified that the miR-320 family, including miR-320 a, miR-320 b, miR-320 c, miR-320 d and miR-320 e, were differentially expressed in adenomaand submucosal invasive carcinoma. The mi R-320 family, which inhibits cell proliferation, is frequently downregulated in colorectal adenoma and submucosal invasive carcinoma tissues. Seven genes including CDK6 were identified to be common in the results of gene expression array and bioinformatics analyses performed to find the target gene of the miR-320 family. We confirmed that mR NA and protein levels of CDK6 were significantly suppressed in colon cancer cell lines with miR-320 family mimics. CDK6 expression was found to increase from non-neoplastic mucosa through adenoma to submucosal invasive carcinoma tissues and showed an inverse correlation with miR-320 family expression.CONCLUSION: MiR-320 family affects colorectal tumor proliferation by targeting CDK6, plays important role in its growth, and is considered to be a biomarker for its early detection. | Toshihiro Tadano Yoichi Kakuta Shin Hamada Yosuke Shimodaira Masatake Kuroha Yoko Kawakami Tomoya Kimura Hisashi Shiga Katsuya Endo Atsushi Masamune Seiichi Takahashi Yoshitaka Kinouchi Tooru Shimosegawa | 2016 | World Journal of Gastrointestinal Oncology2016，8，7： | 9 |
| 10 | Long-term outcomes and prognostic factors of patients with obstructive colorectal cancer: A multicenter retrospective cohort study显示文摘AIM: To investigate the long-term oncologic outcomes and prognostic factors in patients with obstructive colorectal cancer(CRC) at multiple Japanese institutions.METHODS: We identified 362 patients diagnosed with obstructive colorectal cancer from January 1, 2002 to December 31, 2012 in Yokohama Clinical Oncology Group's department of gastroenterological surgery. Among them, 234 patients with stage Ⅱ/Ⅲ disease who had undergone surgical resection of their primary lesions were analyzed, retrospectively. We report the long-term outcomes, the risk factors for recurrence, and the prognostic factors.RESULTS: The five-year disease free survival and cancer-specific survival were 50.6% and 80.3%, respectively. A multivariate analysis showed the ASAPS(HR = 2.23, P = 0.026), serum Albumin ≤ 4.0 g/d L(HR = 2.96, P = 0.007), T4 tumor(HR = 2.73, P = 0.002) and R1 resection(HR = 6.56, P = 0.02) to be independent risk factors for recurrence. Furthermore, poorly differentiated cancers(HR = 6.28, P = 0.009), a T4 tumor(HR = 3.46, P = 0.011) and R1 resection(HR = 6.16, P = 0.006) were independent prognostic factors in patients with obstructive CRC.CONCLUSION: The outcomes of patients with obstructive CRC was poor. T4 tumor and R1 resection were found to be independent prognostic factors for both recurrence and survival in patients with obstructive CRC. | Ishibe Atsushi Ota Mitsuyoshi Yamaguchi Kazuya Kaida Syuhei Kamiya Noriyuki Momiyama Masashi Watanabe Akira Sekizawa Kentaro Kamimukai Nobuyuki Sugimasa Natsuko Watanabe Jun Ichikawa Yasushi Kunisaki Chikara Endo Itaru | 2016 | World Journal of Gastroenterology2016，22，22： | 9 |
| 11 | 导电薄层下三维岩脉的CSAMT响应分析(英文)显示文摘为了研究探测3D导电岩脉状目标体的可控源音频电磁法(CSAMT)的最佳观测装置,我们用压缩积分方程法数值模拟了赋存于导电薄层下的3D导电岩脉的电磁场响应.计算结果表明,最有效的源的位置是把发射源沿岩脉的走向放置.相对于其他几种装置,这种观测装置得到的异常场与主场的比值最大.利用这种最佳的观测装置,通过将异常场E_(ya)和H_(xa)与噪音作对比,研究了当岩脉的埋深和高度发生变化时岩脉的可探测性问题.当岩脉的顶部埋深增加时,导电岩脉的可探测性降低.岩脉高度的变化对异常场幅值的影响要小于岩脉顶部埋深所产生的影响.所以通常情况下,即便应用了最有效的CSAMT装置,也很难探测到岩脉的高度,应用钻孔中的探测可能会解决这个问题. | 王若 Masashi Endo 底青云 王妙月 | 2010 | 地球物理学报2010，53，3： | 9 |
| 12 | Hybrid Rubisco with Complete Replacement of Rice Rubisco Small Subunits by Sorghum Counterparts Confers C4 Plant-like High Catalytic Activity显示文摘Photosynthetic rate at the present atmospheric condition is limited by the CO2-fixing enzyme ribulose-1,5-bisphosphate carboxylase/oxygenase(Rubisco)because of its extremely low catalytic rate(kcat)and poor affinity for C02(Kc)and specificity for CO2(Sc/O).Rubisco in C4 plants generally shows higher k cat than that in C3 plants.Rubisco consists of eight large subunits and eight small subunits(RbcS).Previously,the chimeric incorporation of sorghum C4-type RbcS significantly increased the k cat of Rubisco in a C3 plant,rice.In this study,we knocked out rice RbcS multigene family using the CRISPR-Cas9 technology and completely replaced rice RbcS with sorghum RbcS in rice Rubisco.Obtained hybrid Rubisco showed almost C4 plant-like catalytic properties,i.e.,higher kcai,higher Kc,and lower Sc/O.Transgenic lines expressing the hybrid Rubisco accumulated reduced levels of Rubisco,whereas they showed slightly but significantly higher photosynthetic capacity and similar biomass production under high C 02 condition compared with wild-type rice.High-resolution crystal structural analysis of the wild-type Rubisco and hybrid Rubisco revealed the structural differences around the central pore of Rubisco and the pC-pD hairpin in RbcS.We propose that such differences,particularly in the pC-pD hairpin,may impact the flexibility of Rubisco catalytic site and change its catalytic properties. | Hiroyoshi Matsumura Keita Shiomi Akito Yamamoto Yuri Taketani Noriyuki Kobayashi Takuya Yoshizawa Shun-ichi Tanaka Hiroki Yoshikawa Masaki Endo Hiroshi Fukayama | 2020 | Molecular Plant2020，13，11： | 8 |
| 13 | Double-balloon endoscopy in the diagnosis and management of GI tract diseases:Methodology,indications,safety,and clinical impact显示文摘AIM: To prospectively evaluate the indications, method-ology, safety, and clinical impact of double-balloon en-doscopy.METHODS: A total of 60 patients with suspected or documented small- or large-bowel diseases were investi-gated by double balloon endoscopy. A total of 103 proce-dures were performed (42 from the oral route, 60 from the anal route, and 1 from the stoma route). The main outcome measurements were the time of insertion and the entire examination, complications, diagnostic yields, and the ability to successfully perform treatment.RESULTS: Observation of the entire small intestine was possible in 10 (40%) of 25 patients with total enteros-copy. The median insertion time was 122 min (range, 74-199 min). Observation of the entire colon was possi-ble in 13 (93%) of 14 patients after failure of total colo-noscopy using a conventional colonoscope. Small-intes-tine abnormalities were found in 20 (43%) of 46 patients with indications of suspected or documented small bowel diseases, obscure GI tract bleeding, or a history of ileus. Endoscopic procedures including tattooing (n = 33), bite biopsy (n = 17), radiographic examination (n = 7), EUS (n = 5), hemostasis (n = 1), polypectomy (n = 5), balloon dilatation (n = 1), endoscopic mucosal resection (n = 1) and lithotripsy (n = 1) were all successfully performed. No relevant technical problems or severe complications were encountered.CONCLUSION: Double balloon endoscopy is a feasible technique that allows adequate small and large bowel examination and potentially various endoscopic proce-dures of small-intestinal lesions. It is safe, useful, and also provides a high clinical impact. | Kazuya Akahoshi Masaru Kubokawa Masahiro Matsumoto Shingo Endo Yasuaki Motomura Jiro Ouchi Mitsuhide Kimura Atsuhiko Murata Michiaki Murayama | 2006 | World Journal of Gastroenterology2006，12，47： | 8 |
| 14 | Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma显示文摘BACKGROUND Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma(HCC). In the present study, we evaluated the potential of early changes in the time-intensity curve(TIC) of arterial phase on contrastenhanced ultrasound(CEUS) as early imaging biomarkers of lenvatinib efficacy.AIM To evaluate the potential of the early changes in the TIC of CEUS as early imaging biomarkers of lenvatinib efficacy in patients with unresectable HCC.METHODS We analyzed 20 consecutive patients with unresectable HCC treated with lenvatinib from March to November 2018. Tumor response at 8 wk was assessed by computed tomography using the modified Response Evaluation Criteria in Solid Tumors(m RECIST). CEUS was performed at baseline before treatment(Day 0) and on day 7(Day 7), and the images were analyzed in the arterial phase for 20 seconds after the contrast agent arrived at the target tumor. Three perfusion parameters were extracted from the TICs: the slope of wash-in(Slope),time to peak(TTP) intensity, and the total area under the curve(AUC) during wash-in. The rate of change in the TIC parameters between Day 0 and Day 7 was compared between treatment responders and non-responders based on m RECIST.RESULTS The rate of change for all TIC parameters showed significant differences between the responders(n = 9) and non-responders(n = 11)(Slope, P = 0.025; TTP, P =0.004; and AUC, P = 0.0003). The area under the receiver operating curve values for slope, TTP, and AUC for the prediction of responders were 0.805, 0.869, and0.939, respectively.CONCLUSION CEUS may be useful for the early prediction of tumor response to lenvatinib therapy in patients with unresectable HCC. | Hidekatsu Kuorda Tamami Abe Yudai Fujiwara Takuya Okamoto Miki Yonezawa Hiroki Sato Kei Endo Takayoshi Oikawa Kei Sawara Yasuhiro Takikawa | 2019 | World Journal of Gastroenterology2019，25，19： | 8 |
| 15 | 胆道肿瘤临床实践指南(英文第三版)显示文摘日本肝胆胰外科学会(JSHBPS)于2007年出版第一版胆道肿瘤(胆管癌、胆囊癌及壶腹癌)临床实践指南,于2014年更新第二版,2021年英文第三版胆道肿瘤临床实践指南围绕6个主题提出若干临床问题,基于相关循证医学证据并组织专家讨论后,最终确定推荐意见、推荐强度以及推荐说明。根据证据推荐分级的评估、制订与评价(GRADE)系统,推荐强度被分为1级(强)或者2级(弱)。英文第三版胆道肿瘤临床实践指南中提出的31个临床问题涵盖:(1)预防性治疗;(2)诊断;(3)胆道引流;(4)外科治疗;(5)化疗;(6)放疗。31个临床问题中,14个问题给予推荐强度为强的推荐意见,14个问题给予推荐强度为弱的推荐意见,剩余的3个问题未给予推荐意见。每条推荐意见都进行推荐强度说明。最新版指南基于循证医学证据,为临床提供了重要建议。未来与癌症登记数据库协作将是评估指南和建立新证据的关键。 | Masato Nagino Satoshi Hirano Hideyuki Yoshitomi Taku Aoki Katsuhiko Uesaka Michiaki Unno Tomoki Ebata Masaru Konishi Keiji Sano Kazuaki Shimada Hiroaki Shimizu Ryota Higuchi Toshifumi Wakai Hiroyuki Isayama Takuji Okusaka Toshio Tsuyuguchi Yoshiki Hirooka Junji Furuse Hiroyuki Maguchi Kojiro Suzuki Hideya Yamazaki Hiroshi Kijima Akio Yanagisawa Masahiro Yoshida Yukihiro Yokoyama Takashi Mizuno Itaru Endo 杨翼飞(译) 仇毓东(译) 赵梦珂(译) 伏旭(译) 蔡正华(译) 毛凉(审校) | 2021 | 中华消化外科杂志2021，20，4： | 7 |
| 16 | A prospective randomized trial of lafutidine vs rabeprazole on post-ESD gastric ulcers显示文摘AIM:To compare the effects of rabeprazole and lafutidine on post-endoscopic submucosal dissection(ESD) gastric ulcers.METHODS:Patients with gastric tumors indicated for ESD were prospectively studied.After ESD,all patients were treated with intravenous omeprazole for the first 3 d.Patients were then randomly assigned to oral lafutidine or rabeprazole.Ulcer size,ulcer size reduction rate,and ulcer stage were evaluated 4 wk later.Occurrence of complication was monitored throughout the 4-wk period.RESULTS:Sixty five patients were enrolled in the study,and 60 patients were subjected to the final analysis.In the lafutidine group(30 lesions in 29 patients),initial and 4-wk post-ESD ulcer sizes were 33.3 ± 9.2 and 10.5 ± 4.8 mm,respectively.In the rabeprazole group(34 lesions in 31 patients),the values were 34.7 ± 11.3 and 11.8 ± 6.7 mm,respectively.Ulcer size reduction rates in lafutidine and rabeprazole groups were 32.3% and 33.5%,respectively(P=0.974).Ulcer stage 4 wk post-ESD did not differ significantly between the two groups(P=0.868).Two cases in the rabeprazole group and no cases in the lafutidine group developed ulcer bleeding during the oral dose period,although the difference of bleeding rate between the two groups was not statistically significant(P=0.157).CONCLUSION:Lafutidine and rabeprazole have equivalent therapeutic effects on post-ESD gastric ulcers. | Tomohiko Richard Ohya Hiroki Endo Kei Kawagoe Tatsuro Yanagawa Katsuhiro Hanawa Ken Ohata Masako Asayama Kantaro Hisatomi Takuma Teratani Toshiaki Gunji Hajime Sato Nobuyuki Matsuhashi | 2010 | World Journal of Gastrointestinal Endoscopy2010，2，1： | 7 |
| 17 | 等离子显示屏(PDP)用新型红色发光体的合成及光学特性显示文摘为开发出等离子显示屏用新型红色荧光体,研究了GdAl3(BO3)4∶Eu,Gd2SiO5∶Eu的紫外和真空紫外发光特性。在147nm激发下GdAl3(BO3)4∶Eu3+呈色坐标为(0.645,0 330)的强红光发射,说明是非常有前途的PDP用红色发光材料。在GdAl3(BO3)4∶Eu3+的激发光谱中,除观察到Eu3+的电荷迁移带(峰值位于258nm)外,还观察到峰值位于155nm的宽带。依据硼酸盐的吸收数据将其归属于BO3基团的吸收。另外观察到Gd3+8S7/2→6I11/2跃迁(274nm)及在真空紫外(158~160nm)激发下,Eu3+的红光发射强度随着Eu3+浓度的增加而减弱,说明BO3基团吸收的能量经Gd3+为媒介转移到Eu3+。分析Gd2SiO5∶Eu的激发光谱,得到Eu3+的电荷迁移带是峰值位于256nm的宽带,峰值位于183nm的宽带可能是Gd3+的电荷迁移带。在256nm激发下Gd2SiO5∶Eu3+呈强红光发射,但是147nm激发下很弱。这是由于真空紫外激发效率低的原因,其特点可由其晶体结构即激活离子所处的环境解释。 | 王育华 ENDO Tadshi | 2003 | 液晶与显示2003，18，5： | 7 |
| 18 | Safety advantage of endocut mode over endoscopic sphincterotomy for choledocholithiasis显示文摘瞄准:评估一个自动地控制的切割系统(endocut 模式) 是否能与常规混合切割模式相比在 EST 以后减少内视镜的括约肌切开术(EST ) 和浆液血淀粉酶过多的复杂并发症率。方法:从 2001 年 1 月到 2003 年 10 月,有胆总管石病的 134 个病人在括约肌切开术的时候被分到任何一个 endocut 模式组或常规混合切割模式组。二个组回顾地在 EST 和浆液淀粉酶以后为复杂并发症被比较水平在前和在过程以后的 24 h。结果:对待的 134 个病人, 79 被分到常规混合切割模式组, 55 组织到 endocut 模式。在年龄,性别,和在在二个组之间的 EST 前的浆液淀粉酶水平没有有效差量。复杂并发症在 endocut 模式组(9%) 的 5 个病人被发现:血淀粉酶过多(比正常高 5 倍) 在 4 并且在 1 的中等胰腺炎。复杂并发症在常规混合切割模式组(16%) 的 13 个病人被发现:在 12 的血淀粉酶过多和在 1 的中等胰腺炎。浆液淀粉酶层次在两个组被提高在 EST (P<0.02 ) 以后的 24 h。在在常规混合切割模式的 EST 以后的 24 h 组织的平均浆液淀粉酶水平在 endocut 模式组(P<0.05 ) 比那显著地高。结论:Endocut 模式由减少血淀粉酶过多在 EST 以后为胰腺炎在常规混合切割模式上提供一个安全优点。 | Hirotada Akiho Yorinobu Sumida Kazuya Akahoshi Atsuhiko Murata Jiro Ouchi Yasuaki Motomura Taisuke Toyomasu Mitsuhide Kimura Masaru Kubokawa Masahiro Matsumoto Shingo Endo Kazuhiko Nakamura | 2006 | World Journal of Gastroenterology2006，12，13： | 6 |
| 19 | Early effects of oral administration of omeprazole and roxatidine on intragastric pH显示文摘Objective:The ideal medication for the treatment of acid-related diseases,e.g.,peptic ulcers,stress-related gastric bleeding,functional dyspepsia,and gastroesophageal reflux disease,should have a rapid onset of action to promote hemostasis and relieve the symptoms.The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor,omeprazole 20 mg,and an H2-receptor antagonist,roxatidine 75 mg.Methods:Ten Helicobacter pylori-negative male subjects participated in this randomized,two-way crossover study.Intragastric pH was monitored continuously for 6 h after single oral administration of omeprazole 20 mg and roxatidine 75 mg.Each administration was separated by a 7-d washout period.Results:During the 6-h study period,the average pH after administration of roxatidine was higher than that after administration of omeprazole(median:4.45 vs.2.65;P=0.0367).Also during the 6-h study period,a longer duration of maintenance at pH above 2,5,and 6 was observed after administration of roxatidine 75 mg than after administration of omeprazole 20 mg(median:90.6% vs.55.2%,P=0.0284;43.7% vs.10.6%,P=0.0125;40.3% vs.3.3%,P=0.0125;respectively).Conclusions:In Helicobacter pylori-negative healthy male subjects,oral administration of roxatidine 75 mg increased the intragastric pH more rapidly than that of omeprazole 20 mg. | Hiroshi IIDA Shingo KATO Yusuke SEKINO Eiji SAKAI Takashi UCHIYAMA Hiroki ENDO Kunihiro HOSONO Yasunari SAKAMOTO Koji FUJITA Masato YONEDA Tomoko KOIDE Hirokazu TAKAHASHI Chikako TOKORO Ayumu GOTO Yasunobu ABE Noritoshi KOBAYASHI Kensuke KUBOTA Eiji GOTOH Shin MAEDA Atsushi NAKAJIMA Masahiko INAMORI | 2012 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2012，13，1： | 6 |
| 20 | 压力下的炭化(英文)显示文摘述评了三类压力下的炭化途径:分解气体自升压状态下的炭化,水热反应和还原CO2成炭。尽管这些在加压状态下形成的不同形态和纳米织构的炭材料具有相当高的收率,然而在很多情况下它们是多种形态炭材料的混合物。述评着眼于温度-压力条件和所用的前驱体的化学组成,讨论了高纯度、分离态的炭球的形成条件。 | Michio INAGAKI Ki Chul PARK Morinobu ENDO | 2010 | 新型炭材料2010，25，6： | 5 |
您所在的机构暂未开通此部分的功能，请联系管理员